HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression.

Abstract
Although B-Raf(V600E) is the most common somatic mutation in papillary thyroid carcinoma (PTC), how it induces tumor aggressiveness is not fully understood. Using gene set enrichment analysis and in vitro and in vivo functional studies, we identified and validated a B-Raf(V600E) gene set signature associated with tumor progression in PTCs. An independent cohort of B-Raf(V600E)-positive PTCs showed significantly higher expression levels of many extracellular matrix genes compared with controls. We performed extensive in vitro and in vivo validations on thrombospondin-1 (TSP-1), because it has been previously shown to be important in the regulation of tumor angiogenesis and metastasis and is present in abundance in tumor stroma. Knockdown of B-Raf(V600E) resulted in TSP-1 down-regulation and a reduction of adhesion and migration/invasion of human thyroid cancer cells. Knockdown of TSP-1 resulted in a similar phenotype. B-Raf(V600E) cells in which either B-Raf(V600E) or TSP-1 were knocked down were implanted orthotopically into the thyroids of immunocompromised mice, resulting in significant reduction in tumor size and fewer pulmonary metastases from the primary carcinoma as compared with the control cells. Treatment of orthotopic thyroid tumors, initiated 1 week after tumor cell implantation with PLX4720, an orally available selective inhibitor of B-Raf(V600E), caused a significant tumor growth delay and decreased distant metastases, without evidence of toxicity. In conclusion, B-Raf(V600E) plays an important role in PTC progression through genes (i.e., TSP-1) important in tumor invasion and metastasis. Testing of a patient's thyroid cancer for B-Raf(V600E) will yield important information about potential tumor aggressiveness and also allow for future use of targeted therapies with selective B-Raf(V600E) inhibitors, such as PLX4720.
AuthorsCarmelo Nucera, Alessandro Porrello, Zeus Andrea Antonello, Michal Mekel, Matthew A Nehs, Thomas J Giordano, Damien Gerald, Laura E Benjamin, Carmen Priolo, Efisio Puxeddu, Stephen Finn, Barbara Jarzab, Richard A Hodin, Alfredo Pontecorvi, Vânia Nose, Jack Lawler, Sareh Parangi
JournalProceedings of the National Academy of Sciences of the United States of America (Proc Natl Acad Sci U S A) Vol. 107 Issue 23 Pg. 10649-54 (Jun 08 2010) ISSN: 1091-6490 [Electronic] United States
PMID20498063 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents
  • Indoles
  • PLX 4720
  • Protein Kinase Inhibitors
  • Sulfonamides
  • Thrombospondin 1
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf
Topics
  • Animals
  • Antineoplastic Agents (therapeutic use)
  • Cell Line, Tumor
  • Disease Progression
  • Female
  • Gene Expression Profiling
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Indoles (therapeutic use)
  • Lung Neoplasms (prevention & control, secondary)
  • Mice
  • Mice, SCID
  • Mutation
  • Protein Kinase Inhibitors (therapeutic use)
  • Proto-Oncogene Proteins B-raf (genetics, metabolism)
  • RNA Interference
  • Signal Transduction
  • Sulfonamides (therapeutic use)
  • Thrombospondin 1 (genetics, metabolism)
  • Thyroid Neoplasms (drug therapy, genetics, metabolism, pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: